Profound Medical Corp. (NASDAQ:PROF) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET
Company Participants
Arun Swarup Menawat – Chairman of the Board & CEO
Mathieu Burtnyk – President
Rashed Dewan – Chief Financial Officer
Stephen Kilmer – Investor Relations
Thomas Tamberrino – Chief Commercial Officer
Conference Call Participants
Benjamin Charles Haynor – Lake Street Capital Markets, LLC, Research Division
Douglas W. Loe – Leede Financial Inc., Research Division
John Glenn McAulay – Stifel, Nicolaus & Company, Incorporated, Research Division
Michael W. Freeman – Raymond James Ltd., Research Division
Scott McAuley – Paradigm Capital Inc., Research Division
Operator
Good day, everyone, and thank you for standing by. Welcome to the Profound Medical Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note that today’s conference is being recorded.
I will now hand the conference over to your speaker host, Stephen Kilmer, Head of Investor Relations. Please go ahead.
Stephen Kilmer
Thank you. Good afternoon, everyone.
Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws in the United States and Canada. All forward-looking statements are based on Profound’s current beliefs, assumptions and expectations and relate to, among other things, any expressed or implied statements regarding future financial performance and position and expectations regarding the efficacy of Profound’s technologies in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma.
Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. No forward-looking statement can be guaranteed. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call. Profound undertakes no obligation to publicly update or revise any forward-looking
#Profound #Medical #Corp #PROF #Earnings #Call #Transcript